Solriamfetol in an eight-week fatigue trial
Young JL et al. · 2025 · Journal of Psychopharmacology
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind comparison of oral solriamfetol 75 mg, titratable to 150 mg, versus placebo. Fatigue was assessed at weeks six and eight.
Dose, route and schedule
Double-blind comparison of oral solriamfetol 75 mg, titratable to 150 mg, versus placebo. Fatigue was assessed at weeks six and eight.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fatigue Symptom Inventory severity | Favored solriamfetol at week eight (p=0.039). The week-six comparison gave p=0.270. | |
| Executive function | Global self-reported executive function favored solriamfetol at week eight (p=0.012). | |
| Adverse events | Sleep loss and headache were among the most common events. |
Small, short trial focused on symptom scores. The abstract gives p-values without a between-group effect size.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Small, short trial focused on symptom scores. The abstract gives p-values without a between-group effect size.
Related publications may cover the same research program or participants.
Source access
Double-blind comparison of oral solriamfetol 75 mg, titratable to 150 mg, versus placebo. Fatigue was assessed at weeks six and eight.
Source reviewed 2026-11-12.
Citation and original source
Original source: Young JL et al.. Solriamfetol in an eight-week fatigue trial Journal of Psychopharmacology 2025.
Molekul research summary: https://molekul.io/research/solriamfetol-mecfs-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry